Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of BufferGel as a Vaginal Contraceptive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* General good health~* Sexually active, at risk for pregnancy, and desiring contraception~* Low-risk for HIV or STD infection~* Single sexual partner who is at low-risk for HIV or STD infection for 6 months prior to study entry~* Expect to have same sexual partner for duration of the study~* Normal cyclic menses with a usual length of 21 to 35 days~* Documented history of at least two spontaneous, normal menstrual cycles since delivery, abortion, or after discontinuing hormonal contraception/hormonal therapy~* Willing to accept a risk of pregnancy~* Willing to engage in an average of 1 to 2 acts of heterosexual vaginal intercourse per week for a period of 6 months~* Willing to be fitted with a diaphragm and use the diaphragm with test product during all acts of heterosexual vaginal intercourse for the duration of the study~* Willing to only use the test product with diaphragm as the sole method of contraception over the course of the study (with the exception of emergency contraceptive pills when indicated)~* Capable of using the product and diaphragm properly~* Willing to keep a diary to record coital information, product use information, information about the use of other vaginal products, and sign and symptom data for self and partner~* Agree not to participate in any other clinical trials during the course of the study~* Written informed consent to participate in the trial~Participant's Sexual Partner Must Not Be/Have~* Infertile~* Treated for Chlamydia trachomatis or Neisseria gonorrhoeae in the 6 months prior to study entry~* HIV infected~* More than one sexual partner in the 4 months prior to study entry~* Engaged in homosexual intercourse~* Shared injection drug needles in the 6 months prior to study entry~* Allergy or sensitivity to spermicides or products containing Nonoxynol 9 or latex~Exclusion Criteria~* Pregnant or desire to become pregnant during the course of the study~* History of infertility or conditions that may lead to infertility~* Allergy or sensitivity to spermicides or products containing Nonoxynol 9 or latex~* History of toxic shock syndrome (TSS)~* Two or more urinary tract infections (UTIs) in the 12 months prior to study entry~* Current suspected or diagnosed urinary tract infection or vaginitis~* Contraindications to pregnancy (medical condition or chronic use of medications contraindicated for pregnancy)~* Treated with antibiotics for pelvic inflammatory disease (PID) without a subsequent intrauterine pregnancy~* More than one sexual partner in the 4 months prior to study entry~* Shared injection drug needles in the 6 months prior to study entry~* HIV infected or suspected HIV infection~* Genital herpes simplex virus (HSV) infection with the first occurrence (initial episode) within 3 months prior to study entry or have clinical evidence of HSV on exam~* Sexually transmitted diseases (STDs) in the 3 months prior to study entry~* Lactating or breastfeeding~* Abnormal vaginal bleeding or spotting in the month prior to study entry~* Lower abdominal or pelvic pain in the month prior to study entry~* Abnormal finding on pelvic examination which, in the view of the study investigator, precludes participation in study~* Vaginal or cervical irritation, including vaginal or cervical epithelial disruption, ulceration, bleeding, petechiae, sloughing, or areas of obvious erythema~* Vaginal or cervical biopsy or surgery in the 3 months prior to study entry~* Vaginal or systemic antibiotics, antivirals, or antifungals in the 14 days prior to study entry~* Depo-Provera injection in the 10 months prior to study~* Vaginal or cervical abnormality that would interfere with the proper placement and retention of test product and diaphragm~* Abnormal Pap smear in the 12 months prior to study entry~* Consume (on average) greater than 2 to 3 alcoholic beverages per day~* Drug abuse (recreational, prescription, or OTC) in the 12 months prior to study entry~* Investigational drug or device use in the month prior to study entry~* Previously participated in or completed this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).